{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:41:19Z","timestamp":1789767679711,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.bcp.2019.06.006","type":"journal-article","created":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T10:39:10Z","timestamp":1559990350000},"page":"173-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells"],"prefix":"10.1016","volume":"167","author":[{"given":"Alice","family":"Raineri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Prodomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Fasoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Gotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Menegazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.06.006_b0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.critrevonc.2006.11.007","article-title":"Novel treatment strategies for malignant melanoma: a new beginning?","volume":"62","author":"Kasper","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bcp.2019.06.006_b0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41419-017-0059-7","article-title":"Cell death-based treatments of melanoma: conventional treatments and new therapeutic strategies","volume":"9","author":"Mattia","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2019.06.006_b0015","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.tips.2013.10.003","article-title":"Challenging resistance mechanisms to therapies for metastatic melanoma","volume":"34","author":"Tentori","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2019.06.006_b0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejmech.2019.01.024","article-title":"Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents \u2013 a recent update","volume":"165","author":"Jain","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2019.06.006_b0025","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.ejca.2008.03.019","article-title":"Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity","volume":"44","author":"Tentori","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2019.06.006_b0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly (ADP-ribose): novel function for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2019.06.006_b0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/DDDT.S150846","article-title":"Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach","volume":"12","author":"Zaffini","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bcp.2019.06.006_b0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.molcel.2009.09.032","article-title":"A nuclear poly(ADP-ribose)-dependent signalosome confers DNA damage-induced IkappaB kinase activation","volume":"36","author":"Stilmann","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2019.06.006_b0045","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1541-7786.MCR-13-0206-T","article-title":"NF-\u03baB activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth","volume":"12","author":"Bailey","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bcp.2019.06.006_b0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1479-5876-10-53","article-title":"NF-\u03baB as potential target in the treatment of melanoma","volume":"10","author":"Madonna","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2019.06.006_b0055","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/0008-5472.CAN-04-0673","article-title":"Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma","volume":"64","author":"Amiri","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2019.06.006_b0060","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/1078-0432.CCR-05-1220","article-title":"BMS-345541 targets inhibitor of \u03baB kinase and induces apoptosis in melanoma: involvement of nuclear factor \u03baB and mitochondria pathways","volume":"12","author":"Yang","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2019.06.006_b0065","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.soc.2013.06.011","article-title":"Targeting the NF-\u03baB pathway in cancer therapy","volume":"22","author":"Erstad","year":"2013","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.bcp.2019.06.006_b0070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2131\/jts.40.349","article-title":"The role of NF-\u03baB in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells","volume":"40","author":"Luo","year":"2015","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.bcp.2019.06.006_b0075","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.humimm.2012.02.002","article-title":"Lipopolysaccharide activates ERK-PARP-1-RelA pathway and promotes nuclear factor-\u03baB transcription in murine macrophages","volume":"73","author":"Liu","year":"2012","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.bcp.2019.06.006_b0080","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1080\/15384101.2016.1235104","article-title":"Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: predictions of drug sensitivity based on PAR-p53-NF-\u03baB interactions","volume":"15","author":"Kwon","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2019.06.006_b0085","unstructured":"European Medicines Agency (EMA). Lynparza recommended for approval in ovarian cancer; 2014. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/lynparza-recommended-approval-ovarian-cancer_en.pdf."},{"key":"10.1016\/j.bcp.2019.06.006_b0090","unstructured":"US Food and Drug Administration (FDA). FDA News release: FDAapproves Lynparza to treat advanced ovarian cancer; 2014. Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm427554.htm."},{"key":"10.1016\/j.bcp.2019.06.006_b0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2019.01.015","article-title":"53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer","volume":"153","author":"Hurley","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2019.06.006_b0100","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-cancerbio-030617-050232","article-title":"Resistance to PARP inhibitors: lessons for preclinical models of BRCA-associated cancer","volume":"3","author":"Gogola","year":"2019","journal-title":"Ann. Rev. Cancer Biol."},{"key":"10.1016\/j.bcp.2019.06.006_b0105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.7150\/ijbs.17240","article-title":"Reverse the resistance to PARP inhibitors","volume":"13","author":"Kim","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2019.06.006_b0110","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.14133","article-title":"PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms","author":"Jiang","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bcp.2019.06.006_b0115","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"10.1016\/j.bcp.2019.06.006_b0120","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-15-3240","article-title":"The PARP Inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical","volume":"76","author":"Oplustil O'Connor","year":"2016","journal-title":"Models. Cancer Res."},{"key":"10.1016\/j.bcp.2019.06.006_b0125","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01247168."},{"key":"10.1016\/j.bcp.2019.06.006_b0130","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/CCO.0000000000000016","article-title":"Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice","volume":"25","author":"Helleday","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bcp.2019.06.006_b0135","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2018.03.049","article-title":"The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer","volume":"149","author":"Wilson","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bcp.2019.06.006_b0140","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1111\/cas.13799","article-title":"Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy","volume":"109","author":"Prasanna","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2019.06.006_b0145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2009.06.067","article-title":"Ribonucleases as potential modalities in anticancer therapy","volume":"625","author":"Ardelt","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2019.06.006_b0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/138920108784567344","article-title":"Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity","volume":"9","author":"Rutkoski","year":"2008","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bcp.2019.06.006_b0155","doi-asserted-by":"crossref","first-page":"10293","DOI":"10.1021\/bi200979k","article-title":"Arginine residues are more effective than lysine residues in eliciting the cellular uptake of onconase","volume":"50","author":"Sundlass","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2019.06.006_b0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.celrep.2015.12.046","article-title":"Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant ovarian cancer","volume":"14","author":"Choi","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2019.06.006_b0165","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.celrep.2018.03.038","article-title":"Multifaceted impact of MicroRNA 493\u20135p on genome-stabilizing pathways induces platinum and PARP inhibitor resistance in BRCA2-mutated carcinomas","volume":"23","author":"Meghani","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2019.06.006_b0170","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/07357900500283143","article-title":"Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase","volume":"23","author":"Costanzi","year":"2005","journal-title":"Cancer Invest."},{"key":"10.1016\/j.bcp.2019.06.006_b0175","first-page":"57","article-title":"Phase-I human clinical-trial of onconase(r) (p-30 protein) administered intravenously on a weekly schedule in cancer-patients with solid tumors","volume":"3","author":"Mikulski","year":"1993","journal-title":"Int. J. Onc."},{"key":"10.1016\/j.bcp.2019.06.006_b0180","first-page":"601","article-title":"Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma","volume":"2","author":"Porta","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.bcp.2019.06.006_b0185","first-page":"779","article-title":"Invitro synergism between a novel amphibian oocytic ribonuclease (onconase(r)) and tamoxifen, lovastatin and Cisplatin, in human ovcar-3 ovarian-carcinoma cell-line","volume":"1","author":"Mikulski","year":"1992","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2019.06.006_b0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0014-5793(99)01623-3","article-title":"Effective expression and purification of recombinant onconase, an antitumor protein","volume":"463","author":"Notomista","year":"1999","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2019.06.006_b0195","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1042\/BCJ20170541","article-title":"Onconase dimerization through 3D domain swapping: structural investigations and increase in the apoptotic effect in cancer cells","volume":"474","author":"Fagagnini","year":"2017","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2019.06.006_b0200","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0021-9258(17)41259-2","article-title":"A spectrophotometric method for the measurement of ribonuclease activity","volume":"164","author":"Kunitz","year":"1946","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.06.006_b0205","doi-asserted-by":"crossref","first-page":"662","DOI":"10.2174\/1573406412666160502154936","article-title":"Tree arachidonoylamide derivatives inhibit pro-inflammatory genes expression by modulating NF-\u03baB and AP1 activity","volume":"12","author":"Gregorelli","year":"2016","journal-title":"Med. Chem."},{"key":"10.1016\/j.bcp.2019.06.006_b0210","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/leu.2010.6","article-title":"GammaH2AX: a sensitive molecular marker of DNA damage and repair","volume":"24","author":"Mah","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2019.06.006_b0215","first-page":"1149","article-title":"Effect of ABT888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells","volume":"53","author":"Fratangelo","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2019.06.006_b0220","doi-asserted-by":"crossref","first-page":"75551","DOI":"10.18632\/oncotarget.12270","article-title":"PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas","volume":"7","author":"Czy\u017c","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2019.06.006_b0225","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.canlet.2008.09.038","article-title":"NEMO-binding domain peptide inhibits proliferation of human melanoma cells","volume":"274","author":"Ianaro","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2019.06.006_b0230","first-page":"212","article-title":"In vitro evaluation of anti-proliferative, anti-inflammatory and pro-apoptotic activities of methanolic extracts of Andrographis nallamalayana Ellis on A375 and B16F10 melanoma cell lines","volume":"6","author":"Purushotham","year":"2016","journal-title":"Biotech"},{"key":"10.1016\/j.bcp.2019.06.006_b0235","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.3892\/ol.2015.3672","article-title":"Effects of Nuclear factor-\u03baB and ERK signal transduction pathway inhibitors on human melanoma cell proliferation in vitro","volume":"10","author":"Huang","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2019.06.006_b0240","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1177\/1947601911412375","article-title":"Ranpirnase interferes with NF-\u03baB pathway and MMP9 activity, inhibiting malignant mesothelioma cell invasiveness and Xenograft Growth","volume":"2","author":"Nasu","year":"2011","journal-title":"Genes Cancer."},{"key":"10.1016\/j.bcp.2019.06.006_b0245","first-page":"1745","article-title":"Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB","volume":"25","author":"Tsai","year":"2004","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2019.06.006_b0250","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/onc.2010.643","article-title":"Onconase mediated NFK\u03b2 downregulation in malignant pleural mesothelioma","volume":"30","author":"Goparaju","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2019.06.006_b0255","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bcp.2018.01.027","article-title":"PARP1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice","volume":"150","author":"Dharwal","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2019.06.006_b0260","first-page":"2261","article-title":"Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells","volume":"39","author":"Lacal","year":"2018","journal-title":"Oncol. Rep."},{"issue":"423","key":"10.1016\/j.bcp.2019.06.006_b0265","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2018.03.008","article-title":"The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-\u03baB activation","volume":"1","author":"Faraoni","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2019.06.006_b0270","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.18632\/oncotarget.2868","article-title":"NF-\u03baB signaling mediates acquired resistance after PARP inhibition","volume":"6","author":"Nakagawa","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2019.06.006_b0275","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/(SICI)1097-0215(19990420)84:2<160::AID-IJC12>3.0.CO;2-R","article-title":"Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions","volume":"84","author":"Moretti","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2019.06.006_b0280","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s13046-018-0982-1","article-title":"TNF-alpha and metalloproteases as key players in melanoma cells aggressiveness","volume":"37","author":"Rossi","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2019.06.006_b0285","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1038\/sj.onc.1203239","article-title":"Activators and target genes of Rel\/NF-\u03baB transcription factors","volume":"18","author":"Pahl","year":"1999","journal-title":"Oncogene"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:06:59Z","timestamp":1757768819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219302254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":57,"alternative-id":["S0006295219302254"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.06.006","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}